Poolbeg Pharma licences RNA-based immunotherapy for respiratory viruses from the University of Warwick 17-Jan-2022 By Rachel Arthur Poolbeg Pharma has in-licenced a novel, intra-nasal RNA-based immunotherapy for respiratory virus infections developed at the University of Warwick.